연구동향 분석
박사

쥐 간 절제 모델에서 Gd-EOB-DTPA 조영제의 약리역동학적 지표를 이용한 간 기능 평가 : Assessment of liver function using pharmacokinetic parameters of Gd-EOB-DTPA in rat hepatectomy model

유명원 2016년

논문상세정보
인용/피인용
' 쥐 간 절제 모델에서 Gd-EOB-DTPA 조영제의 약리역동학적 지표를 이용한 간 기능 평가 : Assessment of liver function using pharmacokinetic parameters of Gd-EOB-DTPA in rat hepatectomy model' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • gd-eob-dtpa
  • hepatectomy
  • liver
  • liverfunctiontest
  • pharmacokinetics
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
179 0

0.0%

' 쥐 간 절제 모델에서 Gd-EOB-DTPA 조영제의 약리역동학적 지표를 이용한 간 기능 평가 : Assessment of liver function using pharmacokinetic parameters of Gd-EOB-DTPA in rat hepatectomy model' 의 참고문헌

  • Zipprich A, Kuss O, Rogowski S, et al. Incorporating indocyanin green clearance into the Model for End Stage Liver Disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis. Gut. 2010;59:963-968.
  • Yamada A, Hara T, Li F, et al. Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging. Radiology. 2011;260:727-733.
  • Watanabe H, Kanematsu M, Goshima S, et al. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations. Radiology. 2011;259:142-150.
  • Vauthey JN, Choti MA, Helton WS. AHPBA/SSO/SSAT Consensus Conference on hepatic colorectal metastases: rationale and overview of the conference. January 25, 2006. Ann Surg Oncol. 2006;13:1259-1260.
  • Utsunomiya T, Shimada M, Hanaoka J, et al. Possible utility of MRI using Gd-EOB-DTPA for estimating liver functional reserve. J Gastroenterol. 2012;47:470-476.
  • Tsuda N, Matsui O. Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi--gadoxetic acid-enhanced MR imaging. Radiology. 2010;256:767-773.
  • Shitara Y, Maeda K, Ikejiri K, et al. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos. 2013;34:45-78.
  • Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, et al. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology. 1992;183:59-64.
  • Schuhmann-Giampieri G, Frenzel T, Schmitt-Willich H. Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. Arzneimittelforschung. 1993;43:927-931.
  • Saito K, Ledsam J, Sourbron S, et al. Assessing liver function using dynamic Gd-EOB-DTPA-enhanced MRI with a standard 5-phase imaging protocol. J Magn Reson Imaging. 2013;37:1109-1114.
  • Rowland M TT. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 4th ed. Philadalphia, Lippincott Williams & Wilkins; 2011.
  • Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009;30:1042-1046.
  • Motosugi U, Ichikawa T, Oguri M, et al. Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging. 2011;29:1047-1052.
  • Meier PJ, Eckhardt U, Schroeder A, et al. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology. 1997;26:1667-1677.
  • Madrahimov N, Dirsch O, Broelsch C, et al. Marginal hepatectomy in the rat: from anatomy to surgery. Ann Surg. 2006;244:89-98.
  • Lagadec M, Doblas S, Giraudeau C, et al. Advanced fibrosis: Correlation between pharmacokinetic parameters at dynamic gadoxetate-enhanced MR imaging and hepatocyte organic anion transporter expression in rat liver. Radiology. 2015;274:379-386.
  • Katsube T, Okada M, Kumano S, et al. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol. 2011;46:277-283.
  • International Transporter C, Giacomini KM, Huang SM, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215-236.
  • Imamura H, Sano K, Sugawara Y, et al. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. Journal of Hepato-Biliary-Pancreatic Surgery. 2005;12:16-22.
  • Gu X, Manautou JE. Regulation of hepatic ABCC transporters by xenobiotics and in disease states. Drug Metab Rev. 2010;42:482-538.
  • Gschwend S, Ebert W, Schultze-Mosgau M, et al. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol. 2011;46:556-566.
  • Goshima S, Kanematsu M, Watanabe H, et al. Gd-EOB-DTPA-enhanced MR imaging: prediction of hepatic fibrosis stages using liver contrast enhancement index and liver-to-spleen volumetric ratio. J Magn Reson Imaging. 2012;36:1148-1153.
  • Gaub J, Iversen J. Rat liver regeneration after 90% partial hepatectomy. Hepatology. 1984;4:902-904.
  • Chen BB, Hsu CY, Yu CW, et al. Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. Eur Radiol. 2012;22:171-180.
  • Cha C. Assessment of hepatic function: implications for the surgical patient. In: Jarnagin W, Blumgart L, eds. Blumgart's surgery of the liver, biliary tract and pancreas, 5th ed. Philadelphia: Elsevier; 2012:58-64.
  • Benet LZ, Zia-Amirhosseini P. Basic principles of pharmacokinetics. Toxicol Pathol. 1995;23:115-123.